Cannara Biotech Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Zohar Krivorot
- Full Time Employees
- 452
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Address
- 333 Decarie Blvd. Montréal QC Canada H4N 3M9
- IPO Date
- Jan 18, 2019
- Website
- cannara.ca
- Similar Companies
- Business
- Cannara Biotech Inc. (TSX-V: LOVE; OTC: LOVFF) engages in the indoor cultivation, processing, and sale of premium-grade cannabis and cannabis-derivative products primarily for the recreational and medical markets in Quebec and across Canada. The vertically integrated company operates through two main segments, cannabis operations and real estate operations, owning two mega facilities in Quebec spanning over 1,650,000 square feet in Farnham and Valleyfield that support up to 100,000 kilograms of annualized cultivation output; its core products include dried flower in small and large formats, pre-rolls, live resin vape cartridges, live resin full spectrum extracts, cannabis oils, hash, rosin, and accessories offered under flagship brands Tribal, Nugz, and Orchid CBD. Founded in 2017 and headquartered in Montreal, Quebec, Cannara Biotech leverages advanced cultivation techniques, automated systems, and low-cost regional inputs to deliver craft-quality AAAA cannabis at disruptive retail pricing to wholesalers and online merchandisers. In recent developments, the company amended and upsized its BMO credit facility by $10 million in August 2025 to fund Phase 1 of post-harvest expansion at Valleyfield, introducing state-of-the-art hang-drying, freezing, trimming, packaging, expanded processing, storage, and butane extraction capabilities to support future cultivation scaling; it activated grow rooms 11 and 12 at Valleyfield in fiscal 2025, boosting annual capacity by nearly 18% to 39,500 kilograms and targeting 50,000 kilograms overall; additionally, Cannara sold underutilized Valleyfield property in August 2025 for net proceeds of $5.45 million to reduce term loan debt, eliminated a limited recourse guarantee in March 2025 saving approximately $375,000 in annual interest, and launched products in new categories like vapes in Quebec while reporting record fiscal 2025 revenue with 25% gross cannabis revenue growth in Q4.
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
Cannara Reports Q2 Fiscal 2026 Results with Continued Profitability, Strong Operating Cash Flow and #1 Retail Market Share in Québec
Video - CEO Clips: Cannara Biotech Graduates to Toronto Stock Exchange
Cannara Biotech Inc. (LOVE) Opens the Market
Cannara Achieves #1 Market Share Position in Québec as of December 2025 and Provides Update on Québec Vape Category Launch
Cannara Announces DTC Eligibility to Facilitate U.S. Investor Access and Strengthens Balance Sheet through completion of Debt-to-Equity Conversion
Cannara Announces Proposed Settlement of Convertible Debenture via Share Issuance
Cannara Announces Grant of Options and RSUs
Cannara Announces Amendment and Upsize of BMO Credit Facility to Support Facility Expansion at Valleyfield
Cannara Biotech Enhances Financial Flexibility Through Strategic Asset Sale
Cannara Secures 5 Key Listings in Québec's New Vape Cartridge Category Including to be Released Live Rosin Vapes
Cannara Biotech to Host Investor Webcast on June 25th, 2025
Cannara Biotech Inc. (LOVFF) Q2 2025 Earnings Call Transcript
Cannara Biotech Announces Appointment of Justin Cohen to Board of Directors
Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
Cannara Biotech Reports Q3 2024 Financial Results
Cannara Biotech Reports Q2 2024 Financial Results
Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion